Ocular toxicity of ethambutol.

Department of Ophthalmology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong.
Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine 03/2006; 12(1):56-60.
Source: PubMed

ABSTRACT To review the literature on ocular toxicity of ethambutol--its background, clinical presentation, toxicity characteristics, management, monitoring, and preventive measures.
Literature search of Medline from 1962 to May 2005.
All related literature in English using the search formula: (ethambutol OR myambutol) AND (eye* OR ophthal* OR ocular) AND (adverse OR toxic).
All information was collected and analysed by authors.
Ethambutol hydrochloride is a commonly used first-line anti-tuberculous agent. Although rare, ocular toxicity in the form of optic neuritis (most commonly retrobulbar neuritis) has been well documented since its first use in the 1960s. Classically described as dose- and duration-related and reversible on therapy discontinuation, reversibility of optic neuritis remains controversial. International guidelines on prevention and early detection of ethambutol-induced ocular toxicity have been published. Nonetheless, opinion of the clinical effectiveness of regular vision tests to enable early detection of toxicity is divided.
The course of ethambutol-induced ocular toxicity is unpredictable. Measures to ensure a high level of awareness in medical staff and patients of this potential adverse effect appear to be the best current preventive method. Classified by the World Health Organization as a place with an intermediate tuberculosis burden and good health infrastructure, Hong Kong is in a good position to examine the unanswered questions about ethambutol-induced ocular toxicity.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ethambutol (EMB) is one of the first-line antimycobacterial drugs used to treat tuberculosis and is also used to treat atypical mycobacterium infections. It is almost always used in combination with other antimycobacterial drugs. Ever since the drug’s introduction in the 1960s, there have been descriptions of optic neuropathy associated with EMB. Despite a clear association of EMB-induced optic neuropathy, many questions remain unanswered, namely, which tests are more accurate to monitor toxicity, how often should they be performed and once the optic neuropathy is present, how much of it is reversible?
    Expert Review of Ophthalmology 03/2014; 9(2).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Optic neuropathy is a severe and well-known complication of ethambutol treatment. If not detected early, it may lead to profound and irreversible vision loss. We report the case of a 83-year-old female patient, referred for rapidly progressive, painless, bilateral visual loss, unimproved after bilateral cataract surgery. Automated Humphrey 24-2 visual field demonstrated bitemporal hemianopia associated with bilateral central scotoma. Brain MRI did not demonstrate any compressive lesion in the chiasmal region. However, on T2-weighted sequences, an area of elevated signal intensity appeared within the optic chiasm, enhancing after gadolinium injection. On detailed history, it was noted that the patient had been on ethambutol for the last 18months, for the treatment of a Mycobacterium avium-related pneumonitis. The incidence of ethambutol-related toxic optic neuropathy has dramatically decreased since the recommendations for regular follow-up of patients treated with ethambutol. This treatment is classically responsible for bilateral central or ceco-central scotoma due to optic neuropathy, although a few cases of bitemporal hemianopia have been reported in the literature, mimicking a compressive chiasmal lesion. However, none of these cases demonstrated a hypersignal in the optic chiasm on brain magnetic resonance imaging (MRI). Bitemporal hemianopia on visual field testing is very suggestive of a chiasmal lesion, which is generally due to a compressive, or more rarely inflammatory, lesion in the sellar region. Toxic chiasmal lesions are rare, but in the absence of any tumoral lesion in the sellar area, a detailed history must be obtained in order to rule out drug toxicity, so as to prevent irreversible visual loss.
    Journal francais d'ophtalmologie 10/2013; · 0.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Effective monitoring of antitubercular drugs including ethambutol (EMB) is important for control of multiple drug resistance. Development of fast, easy and inexpensive methods for detection of low concentrations of EMB, especially near its minimum inhibitory concentration, is important. Results: UPLC method for estimating EMB in rat plasma is developed and validated. The method uses small injection volume (1µl) and elutes EMB at 3.18min with 0.070µg/ml and 0.250µg/ml as limits of detection and quantification, respectively. The intra and inter-day accuracy was 106.01-108.82% and 107.80-109.00%, respectively with precision of <5% in both the cases. Mean extraction recovery of EMB from rat plasma was >97% at three concentration levels, establishing consistency and reproducibility (n=6) of the method. EMB was found to be stable in plasma under different storage and processing conditions. Conclusion: Study reports a highly sensitive and specific isocratic UPLC method for rapid quantization of EMB for use in pharmacokinetics and therapeutic drug monitoring
    RSC Advances 08/2014; · 3.71 Impact Factor


Available from